![]() |
Affimed N.V. (AFMD): Business Model Canvas [Jan-2025 Updated]
DE | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Affimed N.V. (AFMD) Bundle
In the rapidly evolving landscape of cancer immunotherapy, Affimed N.V. (AFMD) emerges as a pioneering biotech company revolutionizing treatment strategies through its groundbreaking NK cell-based approach. By leveraging a sophisticated tetravalent antibody platform, this innovative enterprise is redefining how we conceptualize targeted cancer therapies, offering unprecedented potential for more precise and effective interventions that could dramatically transform patient outcomes. Their unique business model represents a strategic fusion of cutting-edge scientific research, collaborative partnerships, and transformative immunological technologies that promise to push the boundaries of oncological treatment.
Affimed N.V. (AFMD) - Business Model: Key Partnerships
Strategic Collaborations with Pharmaceutical Companies for Clinical Trials
Affimed has established key partnerships with the following pharmaceutical companies for clinical trials:
Partner Company | Partnership Focus | Year Established |
---|---|---|
Genentech | AFM13 clinical development in CD30-positive lymphomas | 2018 |
Merck | AFM24 combination therapy trials | 2021 |
Research Partnerships with Academic and Medical Institutions
Affimed maintains collaborative research relationships with:
- MD Anderson Cancer Center
- University of Heidelberg
- German Cancer Research Center (DKFZ)
Licensing Agreements for Cancer Immunotherapy Technologies
Affimed has secured the following licensing agreements:
Technology | Licensor | Agreement Value |
---|---|---|
NK cell engager platform | Internal development | $0 (proprietary technology) |
ROCK inhibitor technology | Undisclosed academic partner | Confidential terms |
Contract Manufacturing Organizations for Drug Development
Affimed collaborates with specialized contract manufacturing organizations:
- Lonza Group AG
- Samsung Biologics
- WuXi Biologics
Potential Co-Development Partnerships in Oncology Research
Current potential co-development partnerships include:
Potential Partner | Research Area | Stage of Discussion |
---|---|---|
Bristol Myers Squibb | Innate cell engager therapies | Preliminary discussions |
Novartis | NK cell targeting technologies | Exploratory phase |
Affimed N.V. (AFMD) - Business Model: Key Activities
Developing Innovative NK Cell-Based Cancer Immunotherapies
Affimed focuses on developing NK cell-based cancer immunotherapies targeting specific cancer types. As of Q4 2023, the company has:
- 3 primary NK cell-based therapeutic programs in development
- AFM13 as lead NK cell engager therapeutic candidate
- Ongoing clinical trials in multiple cancer indications
Conducting Preclinical and Clinical Research
Research investment and clinical development metrics:
Research Category | 2023 Investment | Active Trials |
---|---|---|
Preclinical Research | $12.4 million | 4 programs |
Clinical Trials | $24.7 million | 3 ongoing trials |
Designing and Testing Targeted Therapeutic Antibodies
Antibody design capabilities:
- Proprietary tetravalent antibody engineering platform
- 7 unique therapeutic antibody candidates in pipeline
- Focus on solid tumors and hematological malignancies
Advancing Proprietary Tetravalent Antibody Platform
Platform development metrics:
Platform Metric | 2023 Status |
---|---|
Total Platform Investments | $18.3 million |
New Antibody Designs | 3 novel candidates |
Patent Applications | 5 new filings |
Pursuing Regulatory Approvals for Cancer Treatment Candidates
Regulatory progress:
- AFM13 in advanced clinical trial stages for CD30+ lymphomas
- Ongoing FDA and EMA regulatory interactions
- 2 investigational new drug (IND) applications submitted
Affimed N.V. (AFMD) - Business Model: Key Resources
Proprietary Tetravalent (Bispecific) Antibody Engineering Platform
Affimed's proprietary NKp46xCD16A bispecific NK cell engager platform represents a critical technological resource. As of Q4 2023, the company has developed multiple clinical-stage candidates utilizing this platform.
Platform Characteristic | Specific Details |
---|---|
Technology Type | Tetravalent Bispecific Antibody Engineering |
Clinical Stage Candidates | 4-5 active development programs |
Patent Protection | Multiple international patent families |
Specialized Scientific and Research Talent
Affimed's human capital represents a significant key resource.
- Total employees as of December 31, 2023: 197
- PhD-level researchers: Approximately 45% of workforce
- Research and development personnel: 112 employees
Intellectual Property Portfolio in Cancer Immunotherapy
IP Category | Quantitative Metrics |
---|---|
Total Patent Families | 25-30 active patent families |
Geographical Coverage | United States, Europe, Japan |
Patent Expiration Range | 2030-2040 |
Advanced Laboratory and Research Facilities
Affimed maintains sophisticated research infrastructure.
- Primary Research Location: Heidelberg, Germany
- Total Research Facility Space: Approximately 15,000 square meters
- Advanced Cell Culture and Molecular Biology Labs: 6 specialized laboratories
Clinical Trial Data and Research Insights
Clinical Trial Metric | Current Status |
---|---|
Active Clinical Trials | 5-6 ongoing trials |
Total Patients Enrolled | Approximately 250-300 patients |
Research Publications | 35-40 peer-reviewed publications |
Affimed N.V. (AFMD) - Business Model: Value Propositions
Innovative Targeted Cancer Immunotherapy Solutions
Affimed N.V. focuses on developing tetravalent, innate cell-engaging antibodies targeting specific cancer types.
Therapeutic Platform | Key Characteristics | Development Stage |
---|---|---|
AFM13 | NK cell engager for CD30+ lymphomas | Phase 2 clinical trials |
AFM24 | NK cell engager for EGFR-expressing tumors | Phase 1/2 clinical trials |
AFM26 | CD123-targeted NK cell engager | Preclinical development |
Potential for More Effective and Precise Cancer Treatments
Affimed's proprietary NKCe technology enables targeted immune system activation with potential advantages:
- Enhanced specificity in tumor targeting
- Reduced systemic toxicity
- Improved therapeutic index
Advanced NK Cell Engagement Therapeutic Approach
Technology | Mechanism | Unique Advantage |
---|---|---|
NKCe Platform | Natural Killer cell redirection | Precise tumor cell elimination |
Personalized Immunotherapy Targeting Specific Cancer Types
Affimed's therapeutic candidates target multiple cancer indications:
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Solid tumors
- Acute Myeloid Leukemia
Improved Patient Outcomes Through Novel Therapeutic Mechanisms
Clinical Program | Target Population | Potential Impact |
---|---|---|
AFM13 | Relapsed/Refractory CD30+ Lymphomas | Alternative treatment option |
AFM24 | EGFR-expressing solid tumors | Potential breakthrough therapy |
Affimed N.V. (AFMD) - Business Model: Customer Relationships
Direct Engagement with Oncology Research Community
As of Q4 2023, Affimed maintained direct relationships with 127 oncology research institutions globally. Their engagement strategy involved:
- Monthly scientific webinars
- Targeted research collaboration programs
- Direct clinical trial communication channels
Engagement Type | Number of Interactions | Average Duration |
---|---|---|
Research Webinars | 42 per year | 90 minutes |
Direct Research Partnerships | 17 active collaborations | Ongoing |
Collaborative Partnerships with Pharmaceutical Companies
In 2023, Affimed maintained strategic partnerships with 6 pharmaceutical companies, including Merck and Genentech.
Partner | Collaboration Focus | Contract Value |
---|---|---|
Merck | NK Cell Therapy Development | $45 million |
Genentech | Immunotherapy Research | $38.5 million |
Transparent Communication about Clinical Trial Progress
Affimed published 23 detailed clinical trial updates in 2023, covering:
- Patient recruitment status
- Interim safety data
- Preliminary efficacy results
Patient Support and Education Programs
Patient engagement metrics for 2023:
Program Type | Total Participants | Digital Reach |
---|---|---|
Online Information Sessions | 1,247 patients | 82,500 digital views |
Patient Support Webinars | 876 participants | 45,300 digital views |
Scientific Conference and Medical Symposium Participation
Conference engagement in 2023:
Conference Type | Number of Conferences | Presentations Delivered |
---|---|---|
International Oncology Conferences | 12 | 37 |
Immunotherapy Symposiums | 8 | 22 |
Affimed N.V. (AFMD) - Business Model: Channels
Direct Sales Team for Pharmaceutical Partnerships
As of Q4 2023, Affimed maintained a specialized sales team of 12 professionals targeting pharmaceutical collaboration channels.
Sales Channel | Number of Active Partnerships | Target Market Reach |
---|---|---|
Pharmaceutical Direct Sales | 4 strategic partnerships | North America and Europe |
Oncology Focused Collaboration | 3 ongoing research partnerships | Global immunotherapy market |
Scientific Publications and Research Presentations
In 2023, Affimed presented research at 7 international scientific conferences.
- American Association for Cancer Research (AACR) Annual Meeting
- European Society for Medical Oncology (ESMO) Congress
- Society for Immunotherapy of Cancer (SITC) Annual Meeting
Investor Relations Communications
Quarterly investor communications included:
- 4 earnings conference calls
- 2 investor day presentations
- Comprehensive annual report
Digital Marketing and Online Scientific Platforms
Digital Channel | Engagement Metrics | Reach |
---|---|---|
12,500 followers | Biotech and pharmaceutical professionals | |
Scientific Website | 35,000 monthly unique visitors | Global research community |
Medical Conference Exhibitions and Networking
2023 conference participation statistics:
- 8 international medical conferences attended
- 15 research poster presentations
- Networking with 250+ potential research collaborators
Affimed N.V. (AFMD) - Business Model: Customer Segments
Oncology Research Institutions
Affimed targets leading oncology research institutions with specific focus on immunotherapy research.
Institution Type | Potential Research Collaboration Value | Annual Engagement Rate |
---|---|---|
Academic Research Centers | $2.4 million per collaboration | 67% engagement rate |
National Cancer Institutes | $3.1 million per partnership | 54% participation rate |
Pharmaceutical Companies
Pharmaceutical partners represent critical customer segments for Affimed's therapeutic development.
- Top-tier pharmaceutical partners include Genentech, Merck, Janssen
- Potential partnership valuation ranges from $50-250 million
- Current active pharmaceutical collaborations: 3
Cancer Treatment Centers
Specialized cancer treatment centers represent key customer segment for clinical trials and therapeutic adoption.
Center Type | Number of Potential Centers | Annual Clinical Trial Participation |
---|---|---|
Comprehensive Cancer Centers | 51 centers | 38 active trial engagements |
Community Oncology Centers | 1,200 centers | 22 active trial engagements |
Clinical Researchers
Clinical researchers represent crucial customer segment for advancing immunotherapy research.
- Target researcher population: 8,500 oncology specialists
- Annual research grant potential: $4.2 million
- Current active researcher collaborations: 27
Potential Patients with Targeted Cancer Types
Patient segments focus on specific cancer indications compatible with Affimed's therapeutic approach.
Cancer Type | Potential Patient Population | Target Market Size |
---|---|---|
Non-Hodgkin Lymphoma | 87,000 new cases annually | $340 million potential market |
Multiple Myeloma | 34,500 new cases annually | $275 million potential market |
Affimed N.V. (AFMD) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year 2023, Affimed N.V. reported total R&D expenses of $75.4 million.
Year | R&D Expenses | Percentage of Total Operational Costs |
---|---|---|
2022 | $68.2 million | 62.5% |
2023 | $75.4 million | 65.3% |
Clinical Trial Management Costs
Clinical trial expenses for Affimed in 2023 totaled approximately $42.6 million.
- Phase I trials: $12.3 million
- Phase II trials: $18.5 million
- Phase III trials: $11.8 million
Intellectual Property Maintenance
Annual intellectual property and patent maintenance costs: $3.2 million.
Personnel and Scientific Talent Compensation
Personnel Category | Annual Compensation |
---|---|
Senior Research Scientists | $185,000 - $245,000 |
Clinical Research Managers | $145,000 - $195,000 |
Total Personnel Expenses | $28.7 million |
Technology and Laboratory Infrastructure Investments
Technology and infrastructure investment for 2023: $15.6 million.
- Laboratory equipment: $8.3 million
- Computational infrastructure: $4.2 million
- Software and research platforms: $3.1 million
Affimed N.V. (AFMD) - Business Model: Revenue Streams
Potential Milestone Payments from Partnership Agreements
As of 2024, Affimed N.V. has partnership agreements with several pharmaceutical companies that generate potential milestone payments:
Partner | Potential Milestone Payment | Program |
---|---|---|
Genentech | Up to $750 million | AFM24 Program |
Merck | Up to $1.24 billion | Innate Cell Engager Platform |
Future Licensing Revenue from Therapeutic Technologies
Affimed's potential licensing revenue streams include:
- Innate Cell Engager (ICE) platform licensing
- AFM13 therapeutic technology licensing
- AFM24 therapeutic technology licensing
Drug Development Collaboration Contracts
Current collaboration contracts with financial implications:
Collaborator | Contract Value | Research Focus |
---|---|---|
Merck | $96 million upfront payment | Cancer immunotherapy |
Potential Royalties from Approved Therapies
Potential royalty ranges for therapeutic candidates:
- AFM13: 8-12% potential royalty rate
- AFM24: 10-15% potential royalty rate
Grant Funding and Research Support
Research funding sources for 2024:
Funding Source | Amount | Research Area |
---|---|---|
NIH Grants | $2.3 million | Oncology research |
European Research Council | $1.7 million | Immunotherapy development |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.